The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE
2
. The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.
Alkyl-, Aryl-, Vinyl-, and Heterosubstituted Organozirconium Compounds. -Selective nucleophiles of low basicity. Preliminary communication
作者:Beat Weidmann、Christopher D. Maycock、Dieter Seebach
DOI:10.1002/hlca.19810640532
日期:1981.7.22
Solutions of the title compounds are accessible from organolithium reagents and trialkoxyzirconium chloride (equation 2). In contrast to their titanium analogues, vinylzirconium reagents are stable enough to be employed. Generally, organozirconium reagents are highly selective aldehyde and ketone carbonylophiles of exceedingly lowbasicity (Tables 1, 2, 3 and typical procedure).